NOVARTIS PHARMA STEIN, AG ,   Switzerland

Solution for infusions 5 mg / 100 ml.

Tablets of 2.5 mg.

Tablets, 50 mg.

Capsules, 0.5 mg.

Tablets, 10 mg.

Concentrate for the preparation of a solution for infusions of 4 mg / 5 ml.

Solution for infusion 4 mg / 100 ml.

Lyophilizate for the preparation of a solution for subcutaneous administration, 150 mg.

Pills, film coated 100 mg, 400 mg.

Tablets, film-coated, 80 mg + 12.5 mg, 160 mg + 12.5 mg, 160 mg + 25 mg, 320 mg + 12.5 mg and 320 mg + 25 mg.

Tablets, film-coated, 5 mg + 160 mg + 12.5 mg, 10 mg + 160 mg + 12.5 mg.

Solution for intraocular administration with ranibizumab 10 mg / ml.

1. To 0.23 ml in a bottle of colorless glass, corked with a rubber stopper, coated with an aluminum cap with a snap-off lid.

By one A vial complete with a needle equipped with a filter,to extract the contents from the vial, a syringe, an injection needle along with an instruction for medical application in a cardboard box.

1. For 0.165 ml of the drug in pre-filled glass syringe, sealed with a rubber stopper with a white polypropylene cover to control the first opening. One by one in advance filled syringe in a blister equipped with a label, along with instructions for medical use in a cardboard box.

Capsules with powder for inhalation, 150 mcg and 300 mcg.

Solution for intravenous and subcutaneous administration, 0.05 mg / ml, 0.1 mg / ml and 0.5 mg / ml.

Microspheres for suspension for intramuscular administration, 10 mg, 20 mg and 30 mg.

Capsules with powder for inhalation, 50 mcg.

Solution for subcutaneous administration 0.3 mg / ml, 0.6 mg / ml and 0.9 mg / ml.

1 ml each in ampoules from colorless glass, the ampoule has a broken point. 6

ampoules are placed into the paper with instructions for use in

cardboard tutu.

Multi-pack. 3, 5 or 10 packs of 6 ampoules.

Film-coated tablets, 5 mg / 80 mg, 5 mg / 160 mg or 10 mg / 160 mg.

Tablets of prolonged action, film-coated, 7.5 mg and 15 mg.